Pilot Study of Crizotinib in Relapsed ALK+ Lymphomas
NCT02419287
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
12
Enrollment
OTHER
Sponsor class
Conditions
Anaplastic Large Cell Lymphoma, ALK-Positive
Interventions
DRUG:
crizotinib
Sponsor
University of Milano Bicocca